Compared with the benchmark incomplete Freund's adjuvant, the composite NPs show a 100-fold higher delivery efficiency (tending to LNs), trigger a 10-fold greater peripheral antigen-specific CD8+ immune memory, demonstrate effective vaccine delivery and effective cancer immunotherapy, and were regarded as a powerful platform for cancer immunotherapy 193. The gene discussed is CD8A; the disease is cancer.